Juliana Beal, MD
@julianarbeal
Medical oncologist at Hospital Israelita Albert Einstein interested in breast cancer, tumor agnostic developments and precision oncology
ID: 963623248209633280
14-02-2018 03:57:40
355 Tweet
335 Followers
295 Following
Dr. Sarah Sammons (Dr Sarah Sammons) delivered an insightful lecture on the Treatment of HER2-Positive #MetastaticBreastCancer at the #HarvardBreastCancerCourse.
Daniel Abravanel MD PhD (Daniel Abravanel, MD/PhD), delivered an excellent lecture on integrating treatment options for ER+ #MetastaticBreastCancer at today’s Breast Cancer: New Horizons, Current Controversies Course. #HarvardBreastCancerCourse.
ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process Annals of Oncology. 🔗ow.ly/rqmR50T6gHt
When a group of brilliant & engaged people from different hospitals, cities & countries comes together, the end result is the development of practice changing tools in oncology! So proud! Thanks Ben Westphalen Vivek Subbiah, MD George Pentheroudakis Diogo Martins Branco esmo.org/newsroom/esmo-…
📢#CancerTherapy claiming #TumourAgnostic potential❓ ✔ ORR≥20% in 2/3 of tumour types investigated (≥4) with ≥5 evaluable patients per tumour type 🔓ESMO - Eur. Oncology Tumour-Agnostic Classifier & Screener (ETAC-S) Annals of Oncology Ben Westphalen Vivek Subbiah, MD George Pentheroudakis et al
I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! Annals of Oncology ESMO - Eur. Oncology Vivek Subbiah, MD Juliana Beal, MD G Curigliano MD PhD Razelle Kurzrock, MD Sewanti Limaye 🇮🇳🇺🇸 Stefan Michiels Joaquin Mateo Niamh Coleman, MD PhD FabriceAndre Elena Garralda
Our ETAC-S paper was published in Annals of Oncology - Juliana Beal, MD (H.I.Albert Einstein) oncodaily.com/url/132174 #AnnalsOfOncology #ETACS #JulianaBeal #OncologyResearch #CancerPublications #MedicalScience #OncoDaily #Oncology #Cancer
New article in press: The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. Ben Westphalen FabriceAndre Vivek Subbiah, MD